# Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

> **NCT04281576** · NA · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Gastric Cancer
- GastroEsophageal Cancer

## Interventions

- **DEVICE:** NovoTTF-100L(P)
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04281576
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-06-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281576, "Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04281576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*